Best ED Telehealth Providers 2026: Ranked Honest Review

Most online erectile dysfunction platforms in 2026 sell compounded multi-ingredient products — sildenafil plus tadalafil plus oxytocin in a dissolvable troche, or a chewable tablet with a single active ingredient at a custom dose — that are not FDA-approved single-agent therapies. Only branded Viagra (sildenafil), Cialis (tadalafil), Stendra (avanafil), Levitra (vardenafil), and their FDA-approved generic equivalents have been through Phase 3 trials and FDA review^[7]. Compounded products are mixed at state-licensed 503A or 503B compounding pharmacies under a valid prescription and are legal, but the FDA does not review them for safety, efficacy, or bioequivalence^[8]. That is the first thing you need to know before you compare prices. The five brands ranked below all operate legally inside that framework. The ranking weights price, drug formulary, state availability, pharmacy partner transparency, multi-product breadth, and honest FDA-status disclosure. Disclosure: Weight Loss Rankings has affiliate relationships with several of the brands on this list. Honesty about FDA status and trial evidence comes before any referral incentive.

Methodology — how we rank

We score each ED telehealth brand on six weighted criteria. This is the same evidence-first methodology we apply to GLP-1 telehealth in our best GLP-1 providers ranking:

1. Price transparency (20%) — published per-month and per-dose pricing on the public site, no dark-pattern hidden fees, clear cancellation terms. Compounded troches at $99–$179 per month vs branded Cialis at $400+ per month is a real spread; the brand should show its number.
2. Drug formulary breadth (20%) — does the platform offer FDA-approved single-agent sildenafil and tadalafil (the safer, more-studied option), compounded multi-ingredient products (the cheaper, less-studied option), or both?
3. State availability (15%) — how many US states are covered. A brand operating in 49 states (the ceiling, excluding one or two restrictive jurisdictions) is materially better than one in 30 states.
4. Pharmacy partner transparency (15%) — is the fulfillment pharmacy named on the public site (e.g., Chemistry Rx, Knight Health), state-licensed, and traceable via the State Board of Pharmacy? Or is it a generic “our partner pharmacy network” with no specific identification?
5. Multi-product breadth (15%) — does the brand also offer hair loss, weight loss, mental health, or dermatology under the same membership? For a patient who wants one telehealth relationship, this matters. For a patient who wants the best price on ED specifically, it doesn't.
6. FDA-status honesty (15%) — does the brand explicitly disclose, on the product page and in marketing copy, that compounded products are not FDA-approved and not bioequivalent to branded sildenafil or tadalafil? Brands that bury this disclosure or imply equivalence to FDA approved drugs lose points.

We do not rank on advertising spend, celebrity endorsements, or affiliate commission rates. The ranking order below would be the same if there were no affiliate relationships at all.

The honest framing — compounded vs FDA-approved

The FDA-approved single-agent ED therapies in the US Orange Book^[7] are sildenafil citrate (Viagra; AB-rated generics widely available since 2017), tadalafil (Cialis; AB-rated generics since 2018), avanafil (Stendra), and vardenafil (Levitra). These four molecules have been studied in pivotal Phase 3 trials — Goldstein 1998 NEJM established sildenafil's efficacy in 532 men with mixed- etiology ED with a clear dose-response curve at 25, 50, and 100 mg^[4]; Porst 2006 established tadalafil once-daily 5 mg as a clinically meaningful low-dose maintenance option^[5]. Both molecules have decades of post-marketing safety data, a known side-effect profile (headache, flushing, dyspepsia, nasal congestion, the well-described nitrate contraindication), and dosing guidance the FDA has reviewed.

Compounded ED products — for example, a dissolvable troche containing sildenafil 30 mg plus tadalafil 5 mg plus oxytocin 50 IU — are different. They are mixed at state-licensed 503A compounding pharmacies under a patient-specific prescription, which is legal under 21 USC 353a^[8]. But:

• The FDA has not reviewed the specific multi-ingredient combination for safety, efficacy, or interaction.
• The combination has not been through a Phase 3 trial at the specific doses sold.
• The product is not bioequivalent to branded Viagra or Cialis — pharmacokinetics depend on the troche base, dissolution rate, and route of administration (sublingual vs swallowed).
• Compounded products cannot legally be marketed as “the same as” or “equivalent to” branded products.

That doesn't make compounded products bad. The active ingredients are well-studied molecules at reasonable doses, the pharmacies are state-licensed, and the price difference is meaningful ($99–$179/month compounded vs $400+/month branded Cialis without insurance). It does mean the marketing framing matters. A platform that says “our compounded sildenafil-tadalafil troche is not FDA-approved and was not studied in the pivotal trials but uses the same active molecules as Viagra and Cialis at clinically reasonable doses prescribed by your licensed physician” is being honest. A platform that implies the compounded product is the same thing for less money is not.

The 2026 ranking — top 5 ED telehealth providers

1. BraveRx — Best overall value for compounded ED

BraveRx (Brave Labs LLC, Miami FL) is our 2026 top pick for compounded ED telehealth. The brand operates in 49 US states (excluding only the small handful of jurisdictions where state board rules block out-of-state 503A dispensing), fulfills through Chemistry Rx (a Pennsylvania-licensed compounding pharmacy with a long public regulatory record), and publishes per-tier pricing on the public product page without requiring an email signup or a paid consultation. The formulary is a sildenafil + tadalafil + oxytocin dissolvable troche at three monthly tiers: $99 entry tier (lower dose, lower frequency), ~$139 standard tier, and $179 high-frequency tier. The clinical intake is a written questionnaire reviewed by a licensed physician; a video visit is offered if the questionnaire flags issues that warrant one. The brand is explicit on the product page that the troche is a compounded formulation, not FDA-approved, and that the active ingredients are the same molecules in Viagra and Cialis — which is the disclosure language we want to see. Weakness: no FDA-approved branded option, no in-house cardiology consultation for patients with significant cardiovascular comorbidity, and the multi-product breadth is limited (ED only). Patients with nitrate use, recent MI/stroke, or complex cardiac history should not start ED therapy by questionnaire-only intake — they need a primary-care or cardiology visit first regardless of which telehealth brand they choose.

2. Hims — Best for FDA-approved single-agent therapy

Hims (Hims & Hers Health, NYSE: HIMS) is the largest publicly traded mens-health telehealth brand in the US and the right pick for a patient who wants FDA-approved single-agent sildenafil or tadalafil rather than a compounded multi-ingredient product. Hims' ED formulary includes generic sildenafil 20/50/100 mg, generic tadalafil 5/10/20 mg (both AB-rated FDA-approved generics under Orange Book entries for the originator branded products^[7]), branded Viagra and Cialis, and a separate “hard mints” chewable compounded product line for patients who prefer the chewable form factor. Pricing on generic single-agent sildenafil starts at approximately $2/dose at the highest quantity tier, which is among the cheapest published pricing in the category. The clinical intake is asynchronous text with licensed clinicians; state coverage is the full 50 states. Strengths: public-company financial disclosure (10-K, 10-Q), full FDA-approved formulary, multi-product membership (hair loss, mental health, dermatology, weight loss). Weakness: the membership-funnel upsell pattern is aggressive — patients report routine cross-sell prompts to other Hims product lines — and the compounded “hard mints” product line carries the same not-FDA-approved framing as every other compounded ED product on the market.

3. Ro (Roman) — Established multi-product marketplace

Ro (formerly Roman) is the other major established US mens-health telehealth brand. The ED formulary is FDA-approved generic sildenafil and tadalafil at competitive per-dose pricing, with branded options available at higher cost. Ro operates across the US, fulfills through a network of licensed pharmacies, and offers multi-product membership spanning ED, weight loss (their GLP-1 program is large), hair loss, and fertility. Strengths: established operational scale, FDA-approved single-agent formulary, integration with their Body Program (GLP-1 weight loss) for patients with comorbid obesity and ED — this matters because weight loss reverses ED in a meaningful fraction of patients (Esposito 2004 JAMA^[1], Esposito 2014 J Sex Med^[2]). Weakness: per-dose pricing on FDA-approved generics is similar to Hims and not meaningfully cheaper; the platform does not offer the deeply discounted compounded multi-ingredient products that purpose-built compounded ED brands like BraveRx do. If price on ED alone is the priority, Ro is mid-pack rather than category-leading.

4. Rugiet Health — Distinctive compounded troche form factor

Rugiet Health built its brand around a dissolvable troche (a small lozenge that dissolves under the tongue) containing a combination of active ingredients — typically sildenafil + tadalafil + an additional agent like apomorphine or L-arginine. The sublingual route avoids first-pass hepatic metabolism, which in theory produces a faster onset (15–20 minutes vs 30–60 minutes for an oral tablet) and avoids the food-interaction issue that affects oral sildenafil (a high-fat meal can delay sildenafil absorption by up to an hour). Strengths: the form factor is genuinely differentiated, faster onset is real for some patients, and the pricing is competitive with the compounded category. Weakness: the multi-ingredient combination has not been through a Phase 3 trial as a combination product; apomorphine specifically has a side- effect profile (nausea, hypotension) that single-agent sildenafil or tadalafil do not carry. Patients who tolerate plain compounded sildenafil-tadalafil troches well at BraveRx may not gain enough from the additional active ingredients to justify the switch. Patients who do not tolerate plain compounded troches may find the Rugiet formulation a reasonable alternative.

5. BlueChew — Chewable single-agent for one specific preference

BlueChew sells chewable compounded sildenafil and tadalafil tablets — the single-active-ingredient version of the compounded category, in a chewable form factor rather than a swallowed tablet or a sublingual troche. The clinical case is narrower than the brands above: BlueChew is the right pick for a patient who specifically wants a chewable single-agent product, dislikes swallowing tablets, and is comfortable with compounded rather than FDA-approved. The brand fulfills through Knight Health (a Florida-licensed compounding pharmacy) and operates in most US states. Strengths: single-active-ingredient simplicity (no apomorphine or oxytocin in the mix), chewable form factor for tablet-averse patients, transparent monthly subscription pricing. Weakness: chewable compounded sildenafil offers no clinical advantage over a swallowed FDA-approved generic sildenafil tablet at lower cost; the value proposition is form-factor preference only. Patients who would be fine with a $2 generic sildenafil tablet from Hims or Ro should not pay BlueChew's premium for the chewable format unless they specifically prefer it.

Also worth considering — MyDrHank

MyDrHank (Dr. Hank, LLC) is a smaller DTC ED telehealth that did not make the top-5 ranking but deserves a mention for the patient who specifically wants a named-LLC operator with three disclosed pharmacy partners (Dunklau Pharmacy Holdings LLC, InnovaScript, and PCM Venture I Pharmacy) and a price-competitive 6-month sildenafil tier at $25/mo or 6-month tadalafil tier at $30/mo. The flagship MDH Drive rapid-dissolve compounded sildenafil-tadalafil tablet ($45-$59/mo) is a distinct product category. Honest caveats: the homepage carries an uncustomized Lovable.dev page title with a typo (“Plaform”), specific mg dose tiers are not disclosed pre-purchase, no enumerated state list is published, and we did not locate a LegitScript / PCAB / BBB trust badge. Live-verified 2026-05-28.

The weight loss + ED intersection

Erectile dysfunction is strongly associated with obesity, metabolic syndrome, and cardiovascular disease. The Esposito 2004 JAMA trial^[1] randomized 110 obese men with ED (BMI ≥ 30) to either a 2-year intensive lifestyle intervention (Mediterranean-style diet plus exercise counseling) or general healthy-lifestyle information. At 2 years, the intervention group lost a mean of 15 kg, and 31% of the intervention group had a restored normal IIEF-5 score (≥ 22) compared with 5% of the controls. The effect was mediated through CRP, endothelial function (FMD), and the metabolic syndrome score. Esposito 2014^[2] aggregated subsequent RCTs in a meta-analysis and confirmed that body weight loss improves IIEF scores across study designs. Allen 2018^[3]extended the analysis to physical-activity interventions and sexual function more broadly.

The implication for a patient with ED and a BMI ≥ 30 is that weight loss is a legitimate first-line or co-treatment for ED, not just a vague “lifestyle” suggestion. It is reasonable to combine a PDE5 inhibitor (sildenafil or tadalafil) for symptom relief now plus a serious weight-loss program for the underlying physiology — whether that means a Mediterranean-pattern diet, structured exercise, or FDA-approved obesity pharmacotherapy with a GLP-1. Our research articles on the topic:

• Does losing weight reverse ED? The Esposito 2004 evidence — the JAMA trial, the IIEF-5 mechanism, and what fraction of patients see restored function at what weight-loss magnitude.
• Do GLP-1s help with ED? Semaglutide, tirzepatide, and the ED evidence — the (limited) GLP-1-specific ED data, the indirect mechanism via weight loss and glycemic control, and the honest caveat that no pivotal trial has measured IIEF as a primary outcome.

The compounded vs branded decision framework

For a patient choosing between a compounded multi-ingredient product ($99–$179/month) and an FDA-approved generic single-agent ($30–$90/month at the cheaper telehealth brands; closer to $400/month for branded Viagra or Cialis at a retail pharmacy without insurance):

• Choose FDA-approved generic single-agent (Hims, Ro) if: you want the molecules in the Phase 3 trials at the studied doses, you have any meaningful cardiovascular comorbidity, you take other prescription medications with potential CYP3A4 interactions, you have not previously tolerated sildenafil or tadalafil and want to start with a single known molecule, or you simply want the safer-evidence option.
• Choose compounded multi-ingredient (BraveRx, Rugiet, BlueChew) if: you have already used FDA-approved sildenafil or tadalafil at standard doses and want a custom formulation (e.g., a lower-dose tadalafil with a small dose of sildenafil added), the price difference is decisive for adherence, you specifically want a faster-onset sublingual troche, or you prefer the chewable form factor.
• Do not choose either via telehealth (see a doctor in-person) if: you have known cardiovascular disease, recent MI or stroke (within 6 months), take nitrates of any kind, have severe hepatic impairment, have a known retinal disease (e.g., retinitis pigmentosa), or have ED that started suddenly with no obvious cause — new-onset ED can be the first sign of cardiovascular disease and warrants a workup that questionnaire-based telehealth intake cannot provide.

Insurance landscape

ED is overwhelmingly cash-pay in the US in 2026. Commercial insurance plans rarely cover sildenafil or tadalafil for the standard ED indication, on the rationale that ED treatment for non-medical-necessity erectile function is “quality of life” rather than medical-necessity therapy. Coverage is more common when sildenafil is prescribed for pulmonary arterial hypertension (the Revatio indication) or when tadalafil is prescribed for benign prostatic hyperplasia (the Cialis 5 mg daily BPH indication). Medicare Part D does not routinely cover PDE5 inhibitors for ED. Medicaid coverage varies by state and is generally absent or heavily quantity-limited.

The practical implication is that the price comparison between telehealth brands is the price comparison — you are paying the full cost out of pocket either way. A patient with comprehensive prescription coverage may still find that a Costco or Mark Cuban Cost Plus Drugs cash price on generic sildenafil or tadalafil beats every telehealth brand on per-dose price; the telehealth brands are paying for the consultation, the platform, and the prescription convenience, not just the molecule.

Side effects and safety considerations

All PDE5 inhibitors share a similar side-effect profile, well characterized over two decades of post-marketing data: headache, flushing, dyspepsia, nasal congestion, back/muscle pain (more common with tadalafil at the higher once-daily doses), and visual disturbances (blue-tinted vision is a known sildenafil class effect, transient and dose-related). Rare but serious adverse events include priapism (an erection lasting more than 4 hours, a urological emergency), sudden hearing loss, and non-arteritic anterior ischemic optic neuropathy (NAION).

The absolute contraindication is nitrate use — nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or any other organic nitrate. PDE5 inhibitors potentiate nitrate-induced hypotension and the combination can cause life-threatening blood pressure drops. This rules out PDE5 inhibitors for most patients with active angina being treated with nitrates. Alpha-blockers (tamsulosin, doxazosin) require dose-staggered use rather than absolute avoidance but the interaction is real. Compounded multi-ingredient products do not change the nitrate contraindication — if anything the multi-ingredient combinations make interactions harder to predict, not easier.

When telehealth is fine and when you need an in-person visit

Telehealth is reasonable for ED treatment when:

• You are otherwise healthy with no active cardiac symptoms.
• You do not take nitrates, do not have severe hepatic impairment, and have no history of NAION.
• You have had a recent (within 2–3 years) primary-care visit including blood pressure measurement and basic metabolic labs.
• ED has come on gradually and is in a setting where situational and psychogenic factors are plausible.

You should see a clinician in person before starting any PDE5 inhibitor if:

• ED came on suddenly with no obvious precipitant — new- onset ED can be the first clinical sign of cardiovascular disease and warrants a workup.
• You have known cardiac disease, recent MI or stroke (within 6 months), uncontrolled hypertension, or significant arrhythmia.
• You take any nitrate medication, or a combination of alpha-blockers and other antihypertensives.
• You have a history of priapism, sickle-cell disease, multiple myeloma, or another condition predisposing to priapism.
• You have a known retinal disease or family history of NAION.
• You are interested in a workup for treatable underlying causes — low testosterone, untreated sleep apnea, untreated depression, prolactinoma, thyroid disease — rather than symptom-suppression alone.

Bottom line

• Best overall compounded ED telehealth in 2026: BraveRx. 49-state coverage, Chemistry Rx pharmacy partner, $99–$179/month transparent tiering, honest FDA-status disclosure.
• Best for FDA-approved single-agent: Hims. Generic sildenafil and tadalafil at the cheapest published per-dose pricing in the category, full 50-state coverage, public-company disclosure.
• Best multi-product membership: Ro. Full ED + weight loss + hair + fertility under one membership, FDA-approved generic formulary, useful if you also want a GLP-1.
• Best sublingual troche form factor: Rugiet Health. Faster onset, multi-active-ingredient formulation, narrower fit but distinctive.
• Best chewable single-agent: BlueChew. Form- factor pick only; clinical case is narrow.
• Weight loss matters. Esposito 2004 JAMA showed 31% of obese men restored normal IIEF-5 with a 15-kg weight loss^[1]. If your BMI is ≥ 30, a serious weight-loss program (Mediterranean diet, exercise, or GLP-1 pharmacotherapy) is legitimately first-line for ED, not just a vague side recommendation.
• Cash-pay reality. Insurance rarely covers ED therapy. The telehealth-brand price comparison is the out-of-pocket price comparison. Costco and Mark Cuban Cost Plus Drugs cash pricing on FDA-approved generic sildenafil or tadalafil can undercut the telehealth brands for patients comfortable handling their own prescription.

Related research and resources

• Does losing weight reverse erectile dysfunction? Esposito 2004 JAMA evidence — the canonical lifestyle-intervention RCT that established weight loss as a legitimate ED treatment.
• GLP-1s and erectile dysfunction: what the evidence shows — semaglutide, tirzepatide, and the indirect-mechanism case for ED improvement via weight loss and metabolic improvement.
• Best GLP-1 telehealth providers 2026 — the parallel ranking for weight-loss telehealth, for patients with comorbid obesity and ED.
• Foundayo vs Wegovy vs Zepbound — FDA-approved GLP-1 obesity pharmacotherapy options for weight loss as ED co-treatment.

Important disclaimer. This article is educational and does not constitute medical advice. Erectile dysfunction can be the first clinical sign of cardiovascular disease; sudden-onset ED warrants an in-person clinical evaluation, not symptom-suppression alone. PDE5 inhibitors are absolutely contraindicated with nitrate use and require clinical judgment for patients with cardiac disease, severe hepatic impairment, retinal disease, or a history of priapism. Compounded multi-ingredient products are not FDA-approved and have not been studied in pivotal trials at the doses or combinations sold; they are legal under 21 USC 353a when prepared at state-licensed 503A compounding pharmacies under a valid patient-specific prescription, but they are not bioequivalent to branded Viagra or Cialis. Weight Loss Rankings has affiliate relationships with several of the brands ranked above; the ranking order reflects editorial methodology, not commission rates, and would be unchanged in the absence of affiliate revenue. PMIDs and FDA Orange Book entries were verified on 2026-05-28.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if any ranked brand materially changes pricing, state availability, pharmacy partner, or formulary; or if any FDA enforcement action affects the compounded ED category.